Psyence Biomedical Ltd. (NASDAQ:PBM)
| Market Cap | 107.74K-70.4% |
| Revenue (ttm) | 0 |
| Net Income | -753.25K-996.0% |
| EPS | -39.61+1781.0% |
| Shares Out | 19.02K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,062 |
| Open | 5.66 |
| Previous Close | 5.56 |
| Day's Range | 5.51 - 5.82 |
| 52-Week Range | 1.92 - 175.78 |
| Beta | 1.73 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 28, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About PBM
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
$PBM stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in PBM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PBM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PBM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PBM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PBM from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PBM
| ETF | Est. Holding Size |
|---|---|
| PSILAdvisorShares Psychedelics ETF | $1.44M |
Estimated from each fund’s disclosed top holdings × AUM
PBM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PBM’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.